FDA panel backs Allergan's drug for frequent nightly urination

(Reuters) - The benefits associated with Allergan Plc's experimental drug to treat frequent nightly urination outweigh the risks for certain patients, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.